Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (5088)	8/6/1998 2:03:00 PM
From: Peter Singleton	Read Replies (2) of 6136

PB, great note. Sounds like CHIR has an argument there. Along the lines of the INCY license for non-exclusive use of the clone used in small molecule screening. What sort of terms would be justified, in the CHIR vs et al situation? You said something that interested me, that HGSI and MLNM's awarded patents have included antisense rights. I know INCY has filed for those as well. Do you have an opinion on how strong the antisense rights are? vs any claims an ISIP might have, for example. It's something I've wondered about with respect to ISIP's patent estate. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next